arrow
E

Evgenii Shumilov

University Hospital Münster
H指数:15
被引数:834

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma

寻求长期疾病控制:axicabtagene ciloleucel 或同种异基因造血细胞移植治疗复发/难治性大B细胞淋巴瘤的CAR T细胞疗法

2026-08-070
OAAI
Feasibility and safety of rapid glofitamab ramp-up

快速提升glofitamab的可行性与安全性

Leukemia
IF13.4
2026-07-010
OAAI
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases

TecLisTamaB在复发/难治性轻链淀粉样变性中的应用:德国淀粉样变性学会发起的一项回顾性多中心研究

2026-06-160
OAAI
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

嵌合抗原受体T细胞疗法在老年(≥70岁)和年轻多发性骨髓瘤患者中疗效相当且安全性一致:一项多中心回顾性分析

2026-06-020
OAAI
Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers

自体干细胞移植治疗多发性骨髓瘤或淋巴瘤后的健康相关生活质量影响职业活动——来自两家德国三级医疗中心的分析

2026-05-280
OAAI
Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era

异基因造血细胞移植治疗复发或难治性套细胞淋巴瘤:真实世界结局、晚期复发模式及嵌合抗原受体T细胞时代的临床应用价值

2026-05-260
OAAI
Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study

利妥昔单抗、地塞米松、依托泊苷、异环磷酰胺和卡铂(R-DeVIC)在复发或难治性中枢神经系统淋巴瘤中的应用:一项回顾性多中心临床研究

2026-05-010
OA
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party

自体干细胞移植在主要T细胞淋巴瘤实体中的研究:欧洲血液和骨髓移植学会淋巴瘤工作组分析

2026-02-240
OAAI
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party

异基因干细胞移植治疗主要T细胞淋巴瘤实体:EBMT淋巴瘤工作组分析

2026-02-210
OAAI
Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden

早期CAR T细胞疗法与复发/难治性大B细胞淋巴瘤患者的较低血液毒性负担相关

2025-12-220
OAAI
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
Prospective systematic classification of causes of death in the course of multiple myeloma

多发性骨髓瘤病程中死亡原因的前瞻性系统分类

2025-10-200
OA
Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling

克隆性演化和抗凋亡性在治疗中的骨髓增生异常性肿瘤和急性髓系白血病:整合纵向分析的见解

Leukemia
IF13.4
2025-09-190
OAAI
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis

伊decabtagene vicleucel在复发/难治性多发性骨髓瘤伴先前中枢神经系统表现患者中的疗效:一项多中心真实世界分析

2025-08-180
OA
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party

自体干细胞移植在NK/T细胞淋巴瘤中的应用:EBV-DNA在跨国队列中的预后影响——EBMT淋巴瘤工作组的研究

2025-08-150
OAAI
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

双特异性抗体疗法在复发/难治性大B细胞淋巴瘤中CAR T细胞治疗失败后的疗效

2025-04-190
OA